| 引用本文: | 林高通,徐涛,罗俊,王戟峰,王晨明,莫菊彩,胡国新.复方苦参注射液在大鼠体内对伊马替尼药动学的影响[J].中国现代应用药学,2016,33(12):1547-1552. |
| LIN Gaotong,XU Tao,LUO Jun,WANG Jifeng,WANG Chenming,MO Jucai,HU Guoxin.Effects of Fufang Kushen Injection on Pharmacokinetics of Imatinib in Rats[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(12):1547-1552. |
|
| |
|
|
| 本文已被：浏览 2585次 下载 1766次 |
码上扫一扫！ |
|
|
| 复方苦参注射液在大鼠体内对伊马替尼药动学的影响 |
|
林高通1, 徐涛2, 罗俊3, 王戟峰1, 王晨明1, 莫菊彩1, 胡国新4
|
|
1.台州市肿瘤医院, 浙江 温岭 317500;2.宁波市第一医院, 浙江宁波 315000;3.台州市妇幼保健院, 浙江 台州 317700;4.温州医科大学, 浙江 温州 325035
|
|
| 摘要: |
| 目的 建立HPLC测定大鼠血浆中伊马替尼及其代谢产物GCP74588的浓度，并研究不同浓度复方苦参素注射液对伊马替尼及其代谢产物的药动学的影响。方法 将SD大鼠按体质量均衡原则分成复方苦参注射液低、中、高剂量[0.1，0.2，0.4 mL·（100 g）-1，i.p.]组和正常对照组，每组6只，复方苦参注射液连续给药9 d，第10天给予30 mg·kg-1甲磺酸伊马替尼灌胃，按时间点采集血样处理并检测。结果 低剂量诱导对伊马替尼及CGP74588均无明显影响；中剂量诱导使伊马替尼的Cmax降低39.68%、CLz/F增加了62.96%、AUC（0-∞）减少35.70%，而对其代谢产物CGP74588无明显影响；高剂量诱导使伊马替尼Cmax降低49.04%、Vz/F增加了1.04倍，CLz/F增加了48.15%、AUC（0-t）减少了33.23%、AUC（0-∞）减少了28.96%，MRT（0-∞）增加了47.31%，而其代谢产物CGP74588的Cmax降低45.15%，CLz/F增加75.29%，AUC（0-∞）降低33.95%、MRT（0-t）增加18.53%。结论 苦参诱导肝脏CYP3A与P-gp使伊马替尼血浆中浓度降低，有可能会导致治疗失败，所以临床医师在使用时应尽量避免合用这2种药物，或者在监测伊马替尼的浓度下使用。 |
| 关键词: 复方苦参注射液 伊马替尼 CGP74588 高效液相色谱法 |
| DOI：10.13748/j.cnki.issn1007-7693.2016.12.014 |
| 分类号: |
| 基金项目:温岭市科技计划项目（2013C31115） |
|
| Effects of Fufang Kushen Injection on Pharmacokinetics of Imatinib in Rats |
|
LIN Gaotong1, XU Tao2, LUO Jun3, WANG Jifeng1, WANG Chenming1, MO Jucai1, HU Guoxin4
|
|
1.Taizhou Cancer Hospital, Wenling 317500, China;2.Ningbo First Hospital, Ningbo 315000, China;3.Taizhou Maternal and Child Health Hospital, Taizhou 317700, China;4.Wenzhou Medical University, Wenzhou 325035, China
|
| Abstract: |
| OBJECTIVE To develop an HPLC method for the determination of imatinib and its metabolites CGP74588, and study the induction effects of Fufang Kushen injection on pharmacokinetics of imatinib and CGP74588 in rats. METHODS Twenty-four SD rats were randomly designated as vehicle control, low-dose, medium-dose and high-dose[0.1, 0.2, 0.4 mL·(100 g)-1, i.p.] Fufang Kushen injection treatment groups. The treatment were given once a day for 9 consecutive days. On the experimental day (day 10), rats were treated with the imatinib (30 mg·kg-1) orally. RESULTS Low-dose Fufang Kushen injection does not influence the pharmacokinetics of imatinib and GCP74588. However, the effects of the medium-and high-dose Fufang Kushen injection on imatinib were significant. In medium-dose group, the Cmax and AUC(0-∞) of imatinib reduced 39.68% and 35.70%, while the CLz/F increased 62.96%, but it had no obvious effect on its metabolites CGP74588. In high-dose group, imatinib Cmax and AUC(0-t) were decreased by 49.04% and 33.23%, while Vz/F, CLz/F and MRT(0-∞) were increased by 1.04 times, 48.15% and 47.31%, respectively. Meanwhile, its metabolites CGP74588 Cmax and AUC(0-∞) reduced 45.15% and 33.95%, with 75.29% and 18.53% increase in CLz/F and MRT(0-t). CONCLUSION The induction of medium-dose and high-dose Fufang Kushen injection may be related to the induction sites of CYP3A4 and P-gp. In clinical, when imatinib was co-administrated with Fufang Kushen injection, dose adjustment of imatinib should be taken into account. |
| Key words: Fufang Kushen injection Imatinib CGP74588 HPLC |
|
|
|
|
